

ACORDA THERAPEUTICS INC  
Form 8-K  
June 25, 2010

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): June 24, 2010

Acorda Therapeutics, Inc.  
(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction  
of incorporation)

000-50513  
(Commission  
File Number)

13-3831168  
(I.R.S. Employer  
Identification No.)

15 Skyline Drive, Hawthorne, NY  
(Address of principal executive offices)

10532  
(Zip Code)

Registrant's telephone number, including area code: (914) 347-4300

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

The U. S. District Court for the District of New Jersey has set July 1, 2010 as the date for the Markman Hearing in Acorda Therapeutics, Inc. v. Apotex Corp. and Apotex Inc. Acorda Therapeutics, Inc. (“Registrant”) initiated the litigation asserting infringement of its U.S. Patent No. 6,455,557 relating to multiparticulate tizanidine compositions, including those sold by Registrant as Zanaflex Capsules®, in response to its receipt of a Paragraph IV Certification Notice from Apotex Inc. advising that it had submitted an Abbreviated New Drug Application (“ANDA”) to the FDA seeking marketing approval for generic versions of Zanaflex Capsules.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Acorda Therapeutics, Inc.

June 24, 2010

By: /s/ Jane Wasman  
Name: Jane Wasman  
Title: Executive Vice President,  
General Counsel and Secretary

---

